Trial Filter
BETAAn intelligent search tool for clinical trials
Official Title
Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)
Sponsor
Emory University
Enrollment
25
Timeline
Dec 2018 → Oct 2030
About This Study
This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.
Eligibility Criteria
Inclusion Criteria
- 1Pathologically diagnosed high-grade glioma (World Health Organization \[WHO\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma.
- 2Primary tumor located within the supratentorial brain.
- 3Recommended to receive definitive radiation therapy.
- 4Able to receive MRI scans.
- 5Both males and females, and members of all races and ethnic groups are eligible for this trial.
Exclusion Criteria
- 1Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes MRI safety an issue are excluded.
- 2Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate MRI scan are excluded.
- 3Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.
Locations
3 sites participating in this study
Emory Proton Therapy Center
Atlanta, Georgia 30308
Bree R. Eaton, MD
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Bree R. Eaton, MD
Children's Healthcare of Atlanta - Scottish Rite
Atlanta, Georgia 30322
Bree R. Eaton
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →